Comparing two chemotherapy strategies for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study compares two chemotherapy strategies for people with advanced pancreatic cancer who have not yet had treatment. The goal is to see if switching to a different chemotherapy combination (gemcitabine plus nab-paclitaxel) after initial treatment works better than staying on the original chemotherapy (modified FOLFIRINOX).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of pancreatic cancer called pancreatic adenocarcinoma that cannot be removed by surgery or has spread to other parts of the body.
- You have not had any chemotherapy or other cancer treatment for your current pancreatic cancer.
- You are generally in good health and able to take care of yourself (ECOG score of 0 or 1, depending on age).
- Your blood counts, liver and kidney function tests are within safe limits.
- You are willing to provide a sample of your tumor tissue for testing and to follow the study's contraception rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two chemotherapy combinations for people with advanced (locally advanced or metastatic) pancreatic cancer that hasn't been treated yet. The goal is to see which combination works better and has fewer side effects.
This trial compares two different chemotherapy combinations given after surgery to lower the chance of pancreatic cancer coming back. One combines a new drug (HR070803) with two standard drugs (oxaliplatin and S-1), and the other uses a standard three-drug regimen (NALIRIFOX).
This Phase 2 study compares two chemotherapy combinations to treat metastatic pancreatic cancer that has progressed after gemcitabine (with or without Abraxane). It aims to see which combination works better and is tolerable for people with measurable disease.
This study compares two different chemotherapy combinations after surgery for pancreatic cancer. The goal is to see which is better at preventing the cancer from coming back. You would receive either liposomal irinotecan with oxaliplatin and S-1, or gemcitabine with capecitabine.
This trial compares two combinations of chemotherapy drugs for people with advanced pancreatic cancer whose first treatment stopped working. The study tests whether adding oxaliplatin and bevacizumab to liposomal irinotecan works better than a standard combination.
This trial tests whether taking chemotherapy for a longer period before surgery can help people with borderline or locally advanced pancreatic cancer. It aims to see if a longer treatment course leads to better outcomes.
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.